← 產業報告目錄
Next Generation Complement Therapeutics Market Size, Share & Trends Analysis Report By Indication (Paroxysmal Nocturnal Hemoglobinuria, Geographic Atrophy secondary to Age-Related Macular Degeneration, Generalized Myasthenia Gravis, Atypical Hemolytic Uremic Syndrome, Others), Therapeutic Area, Molecule Type, Complement Inhibition, Route Of Administration, Therapy Type, Region And Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-25頁數 179報告編號 INSIGHTACE-b4782e74b4
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The Next Generation Complement Therapeutics Market on a global scale was estimated at USD 5,070.9 Mn in 2024 and is forecasted to attain USD 12,983.6 Mn by 2034, with a projected CAGR of 10.0% between 2025 and 2034.
The Next Generation Complement Therapeutics sector involves advanced pharmaceutical interventions designed to modulate the complement system more precisely, effectively, and safer than earlier therapies. This domain has witnessed notable transformation owing to technological breakthroughs and shifting healthcare dynamics.
Several factors contribute to this trajectory, including heightened appetite for next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region forecasted to deliver the strongest growth trajectory through the forecast period, fueled by demographic shifts and policy support.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Next Generation Complement Therapeutics Market Snapshot
Chapter 4. Global Next Generation Complement Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Porter's Five Forces Analysis
4.6. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.7. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.8. Use/impact of AI on Next Generation Complement Therapeutics Market Industry Trends
4.9. Global Next Generation Complement Therapeutics Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Next Generation Complement Therapeutics Market Segmentation 1: By Indication, Estimates & Trend Analysis
5.1. Market Share by Indication, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
5.2.1. Paroxysmal Nocturnal Hemoglobinuria (PNH)
5.2.2. Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD)
5.2.3. Generalized Myasthenia Gravis (gMG)
5.2.4. Atypical Hemolytic Uremic Syndrome (aHUS)
5.2.5. Others
Chapter 6. Next Generation Complement Therapeutics Market Segmentation 2: By Therapeutic Area, Estimates & Trend Analysis
6.1. Market Share by Therapeutic Area, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapeutic Area:
6.2.1. Hematology
6.2.2. Ophthalmology
6.2.3. Neurology
6.2.4. Immunology/Rheumatology
6.2.5. Other
Chapter 7. Next Generation Complement Therapeutics Market Segmentation 3: By Molecule Type, Estimates & Trend Analysis
7.1. Market Share by Molecule Type, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Molecule Type:
7.2.1. Biologic
7.2.2. Small Molecule
Chapter 8. Next Generation Complement Therapeutics Market Segmentation 4: By Complement Inhibition, Estimates & Trend Analysis
8.1. Market Share by Complement Inhibition, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Complement Inhibition:
8.2.1. C5 Inhibitor
8.2.2. C3 Inhibitor
8.2.3. Other
Chapter 9. Next Generation Complement Therapeutics Market Segmentation 4: By Route of Administration Inhibition, Estimates & Trend Analysis
9.1. Market Share by Route of Administration, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:
9.2.1. Intravenous
9.2.2. Oral
9.2.3. Intravitreal
9.2.4. Subcutaneous
Chapter 10. Next Generation Complement Therapeutics Market Segmentation 4: By Therapy Type, Estimates & Trend Analysis
10.1. Market Share by Therapy Type, 2024 & 2034
10.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapy Type:
10.2.1. Monotherapy
10.2.2. Adjunctive Therapy
Chapter 11. Next Generation Complement Therapeutics Market Segmentation 5: Regional Estimates & Trend Analysis
11.1. Global Next Generation Complement Therapeutics Market, Regional Snapshot 2024 & 2034
11.2. North America
11.2.1. North America Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.2.1.1. US
11.2.1.2. Canada
11.2.2. North America Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
11.2.3. North America Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
11.2.4. North America Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2021-2034
11.2.5. North America Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Complement Inhibition, 2021-2034
11.2.6. North America Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
11.2.7. North America Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
11.3. Europe
11.3.1. Europe Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.3.1.1. Germany
11.3.1.2. U.K.
11.3.1.3. France
11.3.1.4. Italy
11.3.1.5. Spain
11.3.1.6. Rest of Europe
11.3.2. Europe Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
11.3.3. Europe Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
11.3.4. Europe Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2021-2034
11.3.5. Europe Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Complement Inhibition, 2021-2034
11.3.6. Europe Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
11.3.7. Europe Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
11.4. Asia Pacific
11.4.1. Asia Pacific Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.4.1.1. India
11.4.1.2. China
11.4.1.3. Japan
11.4.1.4. Australia
11.4.1.5. South Korea
11.4.1.6. Hong Kong
11.4.1.7. Southeast Asia
11.4.1.8. Rest of Asia Pacific
11.4.2. Asia Pacific Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
11.4.3. Asia Pacific Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
11.4.4. Asia Pacific Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2021-2034
11.4.5. Asia Pacific Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Complement Inhibition, 2021-2034
11.4.6. Asia Pacific Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
11.4.7. Asia Pacific Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
11.5. Rest of the world
11.5.1. Rest of the world Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.5.1.1. Brazil
11.5.1.2. Mexico
11.5.1.3. Rest of Rest of the world
11.5.2. Rest of the world Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
11.5.3. Rest of the world Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
11.5.4. Rest of the world Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2021-2034
11.5.5. Rest of the world Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Complement Inhibition, 2021-2034
11.5.6. Rest of the world Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
11.5.7. Rest of the world Next Generation Complement Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2021-2034
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. Apellis Pharmaceuticals, Inc.
12.2.1.1. Business Overview
12.2.1.2. Key Indication/Service Overview
12.2.1.3. Financial Performance
12.2.1.4. Geographical Presence
12.2.1.5. Recent Developments with Business Strategy
12.2.2. AstraZeneca
12.2.3. ChemoCentryx/Amgen
12.2.4. Iveric Bio/Astellas Company
12.2.5. UCB
12.2.6. Regeneron
12.2.7. Novartis
12.2.8. Genentech/Roche
12.2.9. ImmunAbs Inc.
12.2.10. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們